IRIS
LODOLA, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.651
AS - Asia 7.262
EU - Europa 6.081
SA - Sud America 1.051
AF - Africa 425
Continente sconosciuto - Info sul continente non disponibili 346
OC - Oceania 4
Totale 23.820
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.378
SG - Singapore 2.540
CN - Cina 1.949
IT - Italia 1.667
VN - Vietnam 1.170
IE - Irlanda 826
FI - Finlandia 822
BR - Brasile 813
SE - Svezia 679
DE - Germania 648
HK - Hong Kong 510
FR - Francia 288
ZA - Sudafrica 277
UA - Ucraina 243
BD - Bangladesh 233
NL - Olanda 205
TR - Turchia 202
IN - India 189
GB - Regno Unito 180
CA - Canada 163
RU - Federazione Russa 122
AT - Austria 93
AR - Argentina 84
CI - Costa d'Avorio 70
BE - Belgio 62
ID - Indonesia 61
JP - Giappone 60
MX - Messico 60
ES - Italia 48
PL - Polonia 48
IQ - Iraq 43
KR - Corea 41
PK - Pakistan 38
TH - Thailandia 38
CZ - Repubblica Ceca 37
VE - Venezuela 36
PH - Filippine 32
EC - Ecuador 31
JO - Giordania 26
LT - Lituania 22
CO - Colombia 21
MA - Marocco 20
SA - Arabia Saudita 20
PY - Paraguay 17
UZ - Uzbekistan 16
CL - Cile 15
RO - Romania 14
TW - Taiwan 14
KE - Kenya 13
PE - Perù 12
BO - Bolivia 11
HU - Ungheria 11
MY - Malesia 11
HR - Croazia 10
TN - Tunisia 10
CR - Costa Rica 9
EG - Egitto 9
JM - Giamaica 9
UY - Uruguay 9
IL - Israele 8
AL - Albania 7
ET - Etiopia 7
MD - Moldavia 7
PS - Palestinian Territory 7
AZ - Azerbaigian 6
DZ - Algeria 6
KZ - Kazakistan 6
RS - Serbia 6
SN - Senegal 6
CH - Svizzera 5
DO - Repubblica Dominicana 5
HN - Honduras 5
KG - Kirghizistan 5
LB - Libano 5
NP - Nepal 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
EU - Europa 4
IR - Iran 4
LV - Lettonia 4
NO - Norvegia 4
OM - Oman 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
DK - Danimarca 3
GT - Guatemala 3
NI - Nicaragua 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
AO - Angola 2
AU - Australia 2
BB - Barbados 2
CY - Cipro 2
GE - Georgia 2
GR - Grecia 2
PA - Panama 2
SC - Seychelles 2
TJ - Tagikistan 2
Totale 23.455
Salva come PNG Salva come JPEG
Città #
Singapore 1.263
Ashburn 964
Dublin 820
San Jose 817
Chandler 742
Santa Clara 622
Dallas 577
Parma 542
Hong Kong 479
Beijing 458
Ann Arbor 398
Ho Chi Minh City 366
Jacksonville 295
Boardman 292
Council Bluffs 282
Johannesburg 263
Hanoi 257
Dearborn 246
Munich 243
Los Angeles 211
New York 211
Nanjing 167
Shanghai 164
Izmir 161
Helsinki 153
Lauterbourg 147
Princeton 136
Hefei 129
Milan 121
Wilmington 112
Bremen 79
São Paulo 78
San Mateo 77
Bologna 73
Columbus 72
Abidjan 70
Vienna 70
Shenyang 69
Toronto 67
Buffalo 64
Haiphong 57
Brussels 54
Moscow 54
Tokyo 51
Kunming 49
London 48
Jinan 47
Seattle 46
Hebei 44
Rome 43
Da Nang 42
Frankfurt am Main 42
Nanchang 42
Turku 42
Jakarta 41
Modena 41
The Dalles 41
Düsseldorf 40
Guangzhou 40
Montreal 39
Chicago 38
Des Moines 37
Changsha 35
Dong Ket 34
Seoul 34
Brescia 33
Jiaxing 32
Orem 32
Warsaw 32
Phoenix 30
Rio de Janeiro 30
Woodbridge 30
Tianjin 29
Nuremberg 28
Bangalore 27
Fremont 27
Stockholm 27
Houston 26
San Francisco 26
Denver 25
Mexico City 25
Naples 25
Brooklyn 24
Ankara 23
Chennai 23
Pune 23
Atlanta 22
Amman 21
Bangkok 21
Hangzhou 21
Brno 20
Belo Horizonte 19
Lubbock 19
Manchester 19
Ottawa 19
Dhaka 18
Norwalk 18
Zhengzhou 18
Biên Hòa 17
Curitiba 17
Totale 14.284
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 355
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 303
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 286
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 279
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 263
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 257
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 255
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 251
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 245
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 229
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 226
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 225
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 222
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 222
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 221
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 221
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 219
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 218
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 216
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 214
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 213
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 213
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 210
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 209
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 208
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 205
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 200
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 197
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 196
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 196
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 193
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 193
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 190
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 183
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 182
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 181
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 179
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 179
inibitori eph-ephrin biodisponibili oralmente 178
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 178
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 176
JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations 170
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 169
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 166
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 166
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 163
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 161
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 161
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 160
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 158
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 158
Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions 155
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 155
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 155
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 154
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 153
Structure activity relationship of new EphA2 ligands 153
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 153
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 153
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 153
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 152
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 152
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 151
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 151
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 151
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 150
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 149
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 149
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 148
Applications and Advances of QM/MM methods in Computational Enzymology 145
Aromatic interactions and rotational strengths within protein environment: An electronic structural study on beta-lactamases from class A 145
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 145
Target-hopping: a useful approach to identify novel Eph receptor antagonists 143
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 143
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 143
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 141
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 140
Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin 139
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 139
Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients 138
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 138
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 138
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 138
Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit 138
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 138
Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency 137
A catalytically silent FAAH-1 variant drives anandamide transport in neurons 136
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 136
Different roles for the acyl chain and the amine leaving group in the substrate selectivity of N-Acylethanolamine acid amidase 136
Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations 135
Irreversible EGFR inhibitor compounds with antiproliferative activity 135
Pushing the Boundaries of Vinylogous Reactivity: Catalytic Enantioselective Mukaiyama Aldol Reactions of Highly Unsaturated 2-Silyloxyindoles 135
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 135
Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines 134
In silico drug discovery of melatonin receptor ligands with therapeutic potential 133
Synthesis, Enantiomeric Resolution, and Structure-Activity Relationship Study of a Series of 10,11-Dihydro-5H-Dibenzo[a,d]cycloheptene MT(2) Receptor Antagonists. 133
N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. 133
Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. 133
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 129
Are we using the right pharmacological tools to target EphA4? 129
Totale 17.615
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.009
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.009
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022820 0 24 24 86 58 28 109 100 58 67 35 231
2022/20233.112 314 309 172 240 288 358 41 196 983 45 127 39
2023/20241.256 82 72 42 43 89 270 118 111 46 64 142 177
2024/20254.391 137 217 271 250 455 481 273 263 563 399 382 700
2025/20269.230 796 966 1.110 823 1.200 490 978 310 1.127 725 413 292
2026/2027658 223 435 0 0 0 0 0 0 0 0 0 0
Totale 23.820